Loading institutional data...
Loading institutional data...
No institutional (13F) filings cover this company, so the Overview and 13F tabs are thin. Everything drawn from its SEC filings is here.
Loading snapshot...
Loading financials...
Loading valuation...
Loading analysis...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Ranked against 14 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-09-30.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| INNV | $1.3B | — | 51.0× | 1.3× | 15.9% | 23.0% | -0.3% | -1.1% | -0.9% | -2.1× | 17 |
| OMDA | $1.2B | — | — | 4.6× | 53.2% | 65.7% | -4.9% | -5.6% | -5.6% | — | 29 |
| CSTL | $1.2B | — | — | 3.4× | 3.7% | 79.4% | -7.0% | -5.1% | -5.0% | — | 30 |
| TALK | $874M | 130.5× | 138.9× | 3.8× | 729% | — | 3.4% | 6.7% | 6.7% | -6.2× | 1 |
| AHCO | $791M | — | 5.3× | 0.2× | -0.5% | 18.8% | -2.2% | -4.7% | -2.2% | 3.7× | 43 |
| FLGT | $597M | — | — | 1.9× | 13.8% | 40.6% | -18.8% | -5.4% | -5.4% | — | 22 |
| SBC | $585M | 11.4× | 6.6× | 3.4× | -15.5% | 73.3% | 29.4% | 20.5% | 17.5% | -1.7× | 10 |
| SRTA | $420M | 9.5× | — | 2.1× | 34.3% | 20.9% | 21.0% | 14.8% | 14.8% | — | 25 |
| VMD | $379M | 26.9× | 7.3× | 1.4× | 20.5% | 57.5% | 5.5% | 10.6% | 9.7% | -0.0× | 30 |
| CYH | $340M | 0.6× | — | 0.0× | -1.2% | 85.1% | 4.1% | -36.5% | 5.7% | — | 27 |
| XGN | $211M | — | — | 3.2× | 19.7% | 58.3% | -30.0% | -114% | -49.4% | — | 3 |
| AIRS | $120M | — | 137.6× | 0.8× | -15.8% | — | -7.7% | -13.3% | -8.1% | — | 10 |
| LFMD | $112M | 9.3× | — | 0.6× | 25.3% | 85.7% | 7.4% | 62.0% | 62.0% | — | 15 |
| CFOR | $112M | 3.9× | 4.6× | 3.7× | 481% | — | 78.2% | 74.1% | 74.1% | -0.0× | — |
| PFHO | $12M | 8.6× | 9.6× | 1.8× | 10.7% | — | 20.7% | 10.6% | 10.6% | -2.1× | — |
Peers = companies sharing PFHO's sector (Services-Misc Health & Allied Services, NEC) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Solve the discounted cash flow backwards, then stress-test the assumptions.
Average free cash flow across the last 3 positive fiscal years (FY2023, FY2024, FY2025). Smooths the cycle. Stock compensation is NOT charged — it is added back inside operating cash flow.
To be worth $0.95 today, the market must believe free cash flow compounds -2.2%/yr for a decade (off $906K on the 3-yr avg basis).
The market's -2.2% is more conservative than its 9-yr track record.
Default is 9.0% — this company's computed cost of capital (computed WACC), the same rate the Analysis tab discounts at.
2-stage DCF · 0.01B shares (market data) · net debt -$2.2M
mean 11.2% · volatility σ 51% · implied rate exceeded in 4/9 yrs
Central path = implied -2.2%/yr growth; shaded band = ±1σ (51%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
What the company returns to shareholders — and whether it's covered by cash.
The dividend is comfortably covered — only 3% of free cash flow, leaving room to grow it and fund buybacks. Last year: $37K dividends + $0 buybacks = $37K returned on $1.1M FCF.
1 consecutive years of dividend increases · 1%/yr.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A cash-return story — far more went to shareholders than back into the business (mature, low-reinvestment).
Modest payoff on reinvested capital. Current ROIC on all capital: 11%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit.
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-10-30
How a revenue dollar becomes profit — FY2025
Dividends and buybacks are cash paid out, shown here against the same year's profit for scale — not funded from it.
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.7M 100.0% | $6.1M 100.0% | $5.6M 100.0% | $5.7M 100.0% | $5.4M 100.0% | $6.0M 100.0% | $7.3M 100.0% | $6.8M 100.0% | $6.5M 100.0% | $5.7M 100.0% |
| Cost of Revenue | — | — | — | — | — | — | — | $513K 7.5% | $543K 8.3% | — |
| Selling, General & Admin | $767K 11.4% | $726K 12.0% | $617K 11.0% | $706K 12.3% | $658K 12.2% | $696K 11.5% | $817K 11.1% | $735K 10.8% | $653K 10.0% | $661K 11.6% |
| Total Operating Expenses | $5.7M 85.1% | $5.2M 85.9% | $5.0M 87.9% | $5.1M 88.4% | $4.9M 90.4% | $5.2M 86.4% | $5.7M 77.1% | $4.9M 72.2% | — | $4.7M 83.0% |
| Operating Income | $1.0M 14.9% | $853K 14.1% | $679K 12.1% | $666K 11.6% | $516K 9.6% | $820K 13.6% | $1.7M 22.9% | $1.9M 27.8% | $1.7M 25.9% | $969K 17.0% |
| Interest Expense | $2K 0.0% | $4K 0.1% | $0 0.0% | — | — | — | — | $0 0.0% | $0 0.0% | $0 0.0% |
| Interest & Investment Income | $474K 7.1% | $415K 6.8% | $406K 7.2% | $0 0.0% | $0 0.0% | — | — | — | — | — |
| Other Income (Expense), net | — | — | — | — | — | — | — | $0 0.0% | $0 0.0% | $0 0.0% |
| Pretax Income | $1.9M 28.2% | $1.3M 20.8% | $1.1M 19.3% | $693K 12.1% | $1.2M 22.1% | $820K 13.6% | $1.7M 22.9% | $1.9M 27.8% | $1.7M 25.9% | $969K 17.0% |
| Income Tax Expense | $507K 7.6% | $380K 6.3% | $321K 5.7% | $200K 3.5% | $201K 3.7% | $271K 4.5% | $482K 6.6% | $530K 7.8% | $723K 11.1% | $403K 7.1% |
| Net Income | $1.4M 20.7% | $884K 14.6% | $768K 13.6% | $493K 8.6% | $995K 18.4% | $550K 9.1% | $1.2M 16.3% | $1.4M 20.0% | $964K 14.8% | $567K 10.0% |
| Per Share | ||||||||||
| EPS (Basic) | $0.11 | $0.07 | $0.06 | $0.04 | $0.08 | $0.04 | $0.09 | $0.11 | $0.30 | $0.71 |
| EPS (Diluted) | $0.11 | $0.07 | $0.06 | $0.04 | $0.08 | $0.04 | $0.09 | $0.11 | $0.30 | $0.71 |
| Weighted Avg Shares (Basic) | 12.8M | 12.8M | 12.8M | 12.8M | 12.8M | 12.8M | 12.8M | 12.8M | 3.2M | 800K |
| Weighted Avg Shares (Diluted) | 12.8M | 12.8M | 12.8M | 12.8M | 12.8M | 12.8M | 12.8M | 12.8M | 3.2M | 801K |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-10-30
Where each multiple sits in its own 14-yr range · 41th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
ROE 11% against ROIC 11% — 0% of the return on equity comes from leverage and buybacks rather than from the operating business.
What the company owes vs. what it holds
This shows debt/cash structure and net leverage. The year-by-year maturity schedule is on the Debt & Leverage tab.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 1.6× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 7.5 | — | — | — | — | — | — | — |
| SG&A | 10.8 | 11.1 | 11.5 | 12.2 | 12.3 | 11.0 | 12.0 | 11.4 |
| Operating Income | 27.8 | 22.9 | 13.6 | 9.6 | 11.6 | 12.1 | 14.1 | 14.9 |
| Income Tax | 7.8 | 6.6 | 4.5 | 3.7 | 3.5 | 5.7 | 6.3 | 7.6 |
| Net Income | 20.0 | 16.3 | 9.1 | 18.4 | 8.6 | 13.6 | 14.6 | 20.7 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on PFHO: price, valuation and headline fundamentals from SEC filings. The four questions at the top of the page are where the judgements live.
Earns -2.56pts against its cost of capital — capital is being consumed, not created.
| Period | ROIC | Cost of capital | Spread |
|---|---|---|---|
| FY2019 | 63.6% | 9.1% (today's — no rate published for this year) | 54.6pts |
| FY2020 | 76.8% | 9.1% (today's — no rate published for this year) | 67.7pts |
| FY2021 | 40.1% | 6.3% | 33.8pts |
| FY2022 | 5.0% | 7.9% | -2.9pts |
| FY2023 | 5.7% | 7.9% | -2.2pts |
| FY2024 | 6.2% | 8.6% | -2.4pts |
| FY2025 | 6.5% | 8.2% | -1.7pts |
| Now | 10.6% | 9.1% | 1.6pts |
| Fiscal year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY2016 | not reported | 17.0% | 10.0% |
| FY2017 | 91.7% | 25.9% | 14.8% |
| FY2018 | 92.5% | 27.8% | 20.0% |
| FY2019 | not reported | 22.9% | 16.3% |
| FY2020 | not reported | 13.6% | 9.1% |
| FY2021 | not reported | 9.6% | 18.4% |
| FY2022 | not reported | 11.6% | 8.6% |
| FY2023 | not reported | 12.1% | 13.6% |
| FY2024 | not reported | 14.1% | 14.6% |
| FY2025 | not reported | 14.9% | 20.7% |
Return on equity (11%) and return on invested capital (11%) are within a couple of points in FY2025, so the headline return is the operating return — there is no meaningful leverage effect to strip out.
The spread was positive in only 1 of the last 5 years.
Converts 0.90x of reported profit into cash — adequate, without much margin.
Capex has been below depreciation for 3 consecutive years (0.64x on average over the last 5). Spending less than the asset base is consuming flatters free cash flow now and defers the cost — though depreciation also covers amortisation of acquired intangibles, which capex is not meant to replace.
Missing from our data, so excluded from this answer: share_based_compensation.
No debt, so there is no leverage path to distress.
Balance sheet at 2025-12-31. Undrawn revolving credit is not shown: the tag is collected but not yet mapped through to the API.
No material counter-signal in the checked set: net debt / EBITDA, interest coverage, stressed coverage, maturity schedule vs cash and one year of FCF, liquidity ratios.
At $0.94, free cash flow must compound -2.39%/yr for 10 years. It has done 1.64%/yr over 6 years.
| Fiscal year | FCF growth | Price requires |
|---|---|---|
| FY2020 | −9.5% | −2.4% |
| FY2021 | −60.6% | −2.4% |
| FY2022 | 82.7% | −2.4% |
| FY2023 | 36.1% | −2.4% |
| FY2024 | −27.2% | −2.4% |
| FY2025 | 70.8% | −2.4% |
The percentile ranks the FISCAL-YEAR point, because the distribution behind each strip is built from fiscal-year closes — ranking a TTM figure inside it would compare two different bases. TTM basis: TTM.
The implied rate has been matched or beaten in 3 of the last 6 years.
| Step | Amount | Running total |
|---|---|---|
| Net income | $1M | $1M |
| Share-based comp | not reported | not reported |
| Other non-cash & working capital | −$226,863 | $1M |
| Operating cash flow | $1M | $1M |
| Capex | −$23,279 | $1M |
| Free cash flow | $1M | $1M |
| Fiscal year | Revenue growth | Receivables growth | Gap |
|---|---|---|---|
| FY2020 | -17.6% | -4.6% | 12.9 points |
| FY2021 | -10.6% | -12.7% | -2.1 points |
| FY2022 | 6.3% | 1.6% | -4.7 points |
| FY2023 | -2.0% | 8.3% | 10.3 points |
| FY2024 | 7.7% | 0.8% | -6.9 points |
| FY2025 | 10.7% | -2.3% | -13.0 points |
| Fiscal year | DSO | DIO | DPO | Cash conversion cycle |
|---|---|---|---|---|
| FY2019 | 55.5 days | not reported | not reported | not reported |
| FY2020 | 64.2 days | not reported | not reported | not reported |
| FY2021 | 62.7 days | not reported | not reported | not reported |
| FY2022 | 59.9 days | not reported | not reported | not reported |
| FY2023 | 66.2 days | not reported | not reported | not reported |
| FY2024 | 61.9 days | not reported | not reported | not reported |
| FY2025 | 54.7 days | not reported | not reported | not reported |
| Fiscal year | Accruals / assets |
|---|---|
| FY2019 | 1.1 percent |
| FY2020 | -3.9 percent |
| FY2021 | 5.4 percent |
| FY2022 | -1.8 percent |
| FY2023 | -1.4 percent |
| FY2024 | 1.7 percent |
| FY2025 | 1.7 percent |
Below the line, the asset base is being consumed faster than it is replaced.
Below the line for 3 consecutive years to the latest.
Depreciation here includes amortisation of acquired intangibles — goodwill written down over time, customer lists, acquired technology. Capex does not replace those and is not meant to, so an acquisitive or asset-light company sits below 1.0 permanently and correctly. The signal is cleanest for capital-intensive businesses, where the two measure the same physical base. For that reason this informs the earnings-quality verdict but never caps it.